Beneficial effects of long-term administration of an oral formulation of angiotensin-(1-7) in infarcted rats

International Journal of Hypertension

Volumn 2012, Issue , 2012, Pages

  Marques, Fúlvia D ^a   Melo, Marcos B ^a   Souza, Leandro E ^a   Irigoyen, Maria Claúdia C ^a   Sinisterra, Rúben D ^a   De Sousa, Frederico B ^a   Savergnini, Sílvia Q ^a   Braga, Vinícius B A ^a   Ferreira, Anderson J ^a   Santos, Robson A S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANGIOTENSIN[1-7]; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART INFARCTION; HEART PROTECTION; LEFT CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT RESPONSE;

EID: 84861511227     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2012/795452     Document Type: Article

References (47)

1. WHO, Summary: deaths (000s) by cause, in WHO regions(a), estimates for 2008.
2. Kassiri Z., Zhong J., Guo D., Basu R., Wang X., Liu P. P., Scholey J. W., Penninger J. M., Oudit G. Y., Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circulation: Heart Failure 2009 2 5 446 455 2-s2.0-70350457666 10.1161/CIRCHEARTFAILURE.108.840124
3. Santos R. A. S., Brosnihan K. B., Chappell M. C., Pesquero J., Chernicky C. L., Greene L. J., Ferrario C. M., Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension 1988 11 2, part 2 I153 I157 2-s2.0-0023924404
4. Grobe J. L., Mecca A. P., Lingis M., Shenoy V., Bolton T. A., Machado J. M., Speth R. C., Raizada M. K., Katovich M. J., Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(17). American Journal of PhysiologyHeart and Circulatory Physiology 2007 292 2 H736 H742 2-s2.0-33846987938 10.1152/ajpheart.00937.2006
5. Chawla T., Sharma D., Singh A., Role of the rennin angiotensin system in diabetic nephropathy. World Journal of Diabetes 2010 1 5 141 145
6. Kuba K., Imai Y., Penninger J. M., Angiotensin-converting enzyme 2 in lung diseases. Current Opinion in Pharmacology 2006 6 3 271 276 2-s2.0-33646352935 10.1016/j.coph.2006.03.001 (Pubitemid 43670913)
7. Stegbauer J., johannes.stegbauer@med.uni-duesseldorf.de Potthoff S. A., Quack I., Mergia E., Clasen T., Friedrich S., Vonend O., Woznowski M., Königshausen E., Sellin L., Rump L. C., Chronic treatment with angiotensin-(17) improves renal endothelial dysfunction in apolipoproteinE- deficient mice. British Journal of Pharmacology 2011 163 5 974 983 10.1111/j.1476-5381.2011.01295.x
8. Shenoy V., Ferreira A. J., Qi Y., Fraga-Silva R. A., Díez-Freire C., Dooies A., Jun J. Y., Sriramula S., Mariappan N., Pourang D., Venugopal C. S., Francis J., Reudelhuber T., Santos R. A., Patel J. M., Raizada M. K., Katovich M. J., The angiotensin-converting enzyme 2/angiogenesis-(17)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2010 182 8 1065 1072 2-s2.0-78049352553 10.1164/rccm.200912-1840OC
9. Ferreira A. J., Santos R. A., Almeida A. P., Angiotensin-(17): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001 38 3, part 2 665 668 2-s2.0-0035461695
10. Almeida A. P., Frábregas B. C., Madureira M. M., Santos R. J. S., Campagnole-Santos M. J., Santos R. A. S., Angiotensin-(17) potentiates the coronary vasodilatatory effect of bradykinin in the isolated rat heart. Brazilian Journal of Medical and Biological Research 2000 33 6 709 713 2-s2.0-0342646962 (Pubitemid 30428611)
11. Loot A. E., Roks A. J. M., Henning R. H., Tio R. A., Suurmeijer A. J. H., Boomsma F., Van Gilst W. H., Angiotensin-(17) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002 105 13 1548 1550 2-s2.0-0037007055 10.1161/01.CIR.0000013847.07035.B9 (Pubitemid 34297630)
12. Marques F. D., Ferreira A. J., Sinisterra R., Jacoby B. A., Sousa F. B., Caliari M. V., Silva G. A.B., Melo M. B., Nadu A. P., Souza L. E., Irigoyen M. C.C., Almeida A. P., Santos R. A.S., santos@icb.ufmg.br An oral formulation of angiotensin-(17) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 2011 57 3 477 483 10.1161/ HYPERTENSIONAHA.110.167346
13. Benter I. F., Yousif M. H. M., Anim J. T., Cojocel C., Diz D. I., Angiotensin-(17) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. American Journal of PhysiologyHeart and Circulatory Physiology 2006 290 2 H684 H691 2-s2.0-33644860787 10.1152/ajpheart.00632.2005
14. Al-Maghrebi M., Benter I. F., Diz D. I., Endogenous angiotensin-(17) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacological Research 2009 59 4 263 268 2-s2.0-61349136870 10.1016/j.phrs.2008.12.008
15. Santos R. A. S., Ferreira A. J., Nadu A. P., Braga A. N. G., De Almeida A. P., Campagnole-Santos M. J., Baltatu O., Iliescu R., Reudelhuber T. L., Bader M., Expression of an angiotensin-(17)-producing fusion protein produces cardioprotective effects in rats. Physiological Genomics 2004 17 292 299 2-s2.0-3042723695 10.1152/physiolgenomics.00227.2003 (Pubitemid 38924174)
16. Gironacci M. M., Valera M. S., Yujnovsky I., Peña C., Angiotensin-(17) inhibitory mechanism of norepinephrine release in hypertensive rats. Hypertension 2004 44 5 783 787 2-s2.0-7244240604 10.1161/01.HYP. 0000143850.73831.9d (Pubitemid 39435254)
17. Iwata M., Cowling R. T., Gurantz D., Moore C., Zhang S., Yuan J. X. J., Greenberg B. H., Angiotensin-(17) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. American Journal of PhysiologyHeart and Circulatory Physiology 2005 289 6 H2356 H2363 2-s2.0-28144432331 10.1152/ajpheart.00317.2005 (Pubitemid 41698543)
18. Tallant E. A., Ferrario C. M., Gallagher P. E., Angiotensin-(17) inhibits growth of cardiac myocytes through activation of the mas receptor. American Journal of PhysiologyHeart and Circulatory Physiology 2005 289 4 H1560 H1566 2-s2.0-25444473110 10.1152/ajpheart.00941.2004 (Pubitemid 41368998)
19. Pan C. H., Wen C. H., Lin C. S., Interplay of angiotensin II and angiotensin(17) in the regulation of matrix metalloproteinases of human cardiocytes. Experimental Physiology 2008 93 5 599 612 2-s2.0-42649117475 10.1113/expphysiol.2007.041830 (Pubitemid 351595058)
20. Grobe J. L., Mecca A. P., Mao H., Katovich M. J., Chronic angiotensin-(17) prevents cardiac fibrosis in DOCA-salt model of hypertension. American Journal of PhysiologyHeart and Circulatory Physiology 2006 290 6 H2417 H2423 2-s2.0-33744910056 10.1152/ajpheart.01170.2005 (Pubitemid 43846070)
21. Santos R. A. S., Simões e Silva A. C., Maric C., Silva D. M. R., Machado R. P., De Buhr I., Heringer-Walther S., Pinheiro S. V. B., Lopes M. T., Bader M., Mendes E. P., Lemos V. S., Campagnole-Santos M. J., Schultheiss H. P., Speth R., Walther T., Angiotensin-(17) is an endogenous ligand for the G protein-coupled receptor Mas. Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8258 8263 2-s2.0-0037478671 10.1073/pnas.1432869100 (Pubitemid 36842532)
22. Mazzolai L., Pedrazzini T., Nicoud F., Gabbiani G., Brunner H. R., Nussberger J., Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000 35 4 985 991 2-s2.0-0034024638 (Pubitemid 30303962)
23. Mehta P. K., Griendling K. K., Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. American Journal of PhysiologyCell Physiology 2007 292 1 C82 C97 2-s2.0-33846362954 10.1152/ajpcell.00287.2006 (Pubitemid 46127306)
24. Kuwahara F., Kai H., Tokuda K., Takeya M., Takeshita A., Egashira K., Imaizumi T., Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 2004 43 4 739 745 2-s2.0-1642542466 10.1161/01.HYP.0000118584.33350.7d (Pubitemid 38405580)
25. Border W. A., Noble N. A., Transforming growth factor β in tissue fibrosis. New England Journal of Medicine 1994 331 19 1286 1292 2-s2.0-0028109801 10.1056/NEJM199411103311907 (Pubitemid 24333194)
26. Pauschinger M., Knopf D., Petschauer S., Doerner A., Poller W., Schwimmbeck P. L., Kühl U., Schultheiss H. P., Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 1999 99 21 2750 2756 2-s2.0-0033153131 (Pubitemid 29250020)
27. Li G., Li R. K., Mickle D. A. G., Weisel R. D., Merante F., Ball W. T., Christakis G. T., Cusimano R. J., Williams W. G., Elevated insulin-like growth factor-I and transforming growth factor- β 1 and their receptors in patients with idiopathic hypertrophic obstructive cardiomyopathy: a possible mechanism. Circulation 1998 98 19 II144 II150 2-s2.0-0344589413 (Pubitemid 28512181)
28. Takahashi N., Calderone A., Izzo N. J., Maki T. M., Marsh J. D., Colucci W. S., Hypertrophic stimuli induce transforming growth factor- β 1 expression in rat ventricular myocytes. Journal of Clinical Investigation 1994 94 4 1470 1476 2-s2.0-0028025683 (Pubitemid 24309866)
29. Hao J., Ju H., Zhao S., Junaid A., Scammell-La Fleur T., Dixon I. M. C., Elevation of expression of Smads 2, 3, and 4, decorin and TGF- β in the chronic phase of myocardial infarct scar healing. Journal of Molecular and Cellular Cardiology 1999 31 3 667 678 2-s2.0-0033104679 10.1006/jmcc.1998.0902 (Pubitemid 29121651)
30. Bujak M., Frangogiannis N. G., The role of TGF- β signaling in myocardial infarction and cardiac remodeling. Cardiovascular Research 2007 74 2 184 195 2-s2.0-34047148354 10.1016/j.cardiores.2006.10.002 (Pubitemid 46517504)
31. Boluyt M. O., O'Neill L., Meredith A. L., Bing O. H. L., Brooks W. W., Conrad C. H., Crow M. T., Lakatta E. G., Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding extracellular matrix components. Circulation Research 1994 75 1 23 32 2-s2.0-0028283259 (Pubitemid 24187732)
32. Lula I., Denadai A. L., Resende J. M., de Sousa F. B., de Lima G. F., Pilo-Veloso D., Heine T., Duarte H. A., Santos R. A. S., Sinisterra R. D., Study of angiotensin-(17) vasoactive peptide and its β -cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. Peptides 2007 28 11 2199 2210 2-s2.0-35349001774 10.1016/j.peptides.2007.08.011 (Pubitemid 47610792)
33. Botelho L. M.O., Block C. H., Khosla M. C., Santos R. A. S., Plasma angiotensin(17) immunoreactivity is increased by salt load, water deprivation, and hemorrhage. Peptides 1994 15 4 723 729 10.1016/0196-9781(94)90103-1 (Pubitemid 24221850)
34. Torabi A., Cleland J. G. F., Khan N. K., Loh P. H., Clark A. L., Alamgir F., Caplin J. L., Rigby A. S., Goode K., The timing of development and subsequent clinical course of heart failure after a myocardial infarction. European Heart Journal 2008 29 7 859 870 2-s2.0-41849135734 10.1093/eurheartj/ ehn096 (Pubitemid 351499497)
35. Minicucci M. F., Azevedo P. S., Polegato B. F., Paiva S. A.R., Zornoff L. A.M., lzornoff@fmb.unesp.br Heart failure after myocardial infarction: clinical implications and treatment. Clinical Cardiology 2011 34 7 410 414 10.1002/clc.20922
36. Pfeffer M. A., Pfeffer J. M., Lamas G. A., Development and prevention of congestive heart failure following myocardial infarction. Circulation 1993 87 5 IV120 IV125 2-s2.0-0027230442 (Pubitemid 23135659)
37. Pfeffer M. A., Braunwald E., Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990 81 4 1161 1172 2-s2.0-0025266820 (Pubitemid 20119612)
38. Cikes M., Sutherland G. R., Anderson L. J., Bijnens B. H., The role of echocardiographic deformation imaging in hypertrophic myopathies. Nature Reviews Cardiology 2010 7 7 384 396 2-s2.0-77954177637 10.1038/nrcardio.2010.56
39. Amundsen B. H., Helle-Valle T., Edvardsen T., Torp H., Crosby J., Lyseggen E., Stoylen A., Ihlen H., Lima J. A. C., Smiseth O. A., Slordahl S. A., Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging. Journal of the American College of Cardiology 2006 47 4 789 793 2-s2.0-29344469684 10.1016/j.jacc.2005.10.040 (Pubitemid 43243102)
40. Sun Y., Zhang J. Q., Zhang J., Ramires F. J. A., Angiotensin II, transforming growth factor- β 1 and repair in the infarcted heart. Journal of Molecular and Cellular Cardiology 1998 30 8 1559 1569 2-s2.0-0032142834 10.1006/jmcc.1998.0721 (Pubitemid 28418646)
41. Dostal D. E., Regulation of cardiac collagen: angiotensin and cross-talk with local growth factors. Hypertension 2001 37 3 841 844 2-s2.0-0035100731 (Pubitemid 32221601)
42. Rosenkranz S., TGF- β 1 and angiotensin networking in cardiac remodeling. Cardiovascular Research 2004 63 3 423 432 2-s2.0-3242806007 10.1016/j.cardiores.2004.04.030 (Pubitemid 38970186)
43. Matsumoto-Ida M., Takimoto Y., Aoyama T., Akao M., Takeda T., Kita T., Activation of TGF- β 1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. American Journal of PhysiologyHeart and Circulatory Physiology 2006 290 2 H709 H715 2-s2.0-31444444985 10.1152/ajpheart.00186.2005
44. Gomes E. R. M., Lara A. A., Almeida P. W. M., Guimarães D., Resende R. R., Campagnole-Santos M. J., Bader M., Santos R. A. S., Guatimosim S., Angiotensin-(17) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3′5′-cyclic monophosphate-dependent pathway. Hypertension 2010 55 1 153 160 2-s2.0-73849095442 10.1161/HYPERTENSIONAHA.109. 143255
45. Santos R. A. S., Castro C. H., Gava E., Pinheiro S. V. B., Almeida A. P., De Paula R. D., Cruz J. S., Ramos A. S., Rosa K. T., Irigoyen M. C., Bader M., Alenina N., Kitten G. T., Ferreira A. J., Impairment of in vitro and in vivo heart function in angiotensin-(17) receptor mas knockout mice. Hypertension 2006 47 5 996 1002 2-s2.0-33646161714 10.1161/01.HYP.0000215289.51180.5c (Pubitemid 44297574)
46. Santiago N. M., Guimarães P. S., Sirvente R. A., Oliveira L. A. M., Irigoyen M. C., Santos R. A. S., Campagnole-Santos M. J., Lifetime overproduction of circulating angiotensin-(17) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. Hypertension 2010 55 4 889 896 2-s2.0-77950505611 10.1161/HYPERTENSIONAHA.110. 149815
47. Benter I. F., ibenter@hsc.edu.kw Yousif M. H. M., Angiotensin-(17) prevents diabetes-induced cardiovascular dysfunction. American Journal of PhysiologyHeart and Circulatory Physiology 2007 292 1 H666 H672 10.1152/ajpheart.00372.2006 (Pubitemid 46105230)